Drugs - HealthQuill

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

by HealthQuill
January 15, 2025
0 Comments

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid tumours, for $2.5 billion in cash.

Drugs Health Medical

Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.

by HealthQuill
January 14, 2025
0 Comments

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to a J&J statement.

Drugs Medical Pharma

Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.

by HealthQuill
January 14, 2025
0 Comments

FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.

Drugs Pharma Research

Pfizer’s experimental drug improves survival rates in hard-to-treat bladder cancer

Bharti Jayshankar January 11, 2024: In a breakthrough for bladder cancer treatment, Pfizer’s experimental anti-PD-1 therapy demonstrated superior efficacy compared to the current.

by HealthQuill
January 11, 2025
0 Comments

Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of 30%, according to a Securities and Exchange Commission filing.

Drugs Medical Pharma

Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million

Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.

by HealthQuill
January 11, 2025
0 Comments

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.

Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

by HealthQuill
January 11, 2025
0 Comments

Pizer Inc.’s late-stage trial of an antibody treatment for a certain type of bladder cancer has shown significant improvement in time patients remained free of complications, according to a company statement.

Drugs Health Medical

Pfizer’s trial antibody for type of bladder cancer meets main goal

Pizer Inc.’s late-stage trial of an antibody treatment for a certain type of bladder cancer has shown significant improvement in time patients remained.

by HealthQuill
January 10, 2025
0 Comments

Loneliness may contribute to a higher risk of heart disease, stroke and susceptibility to infections, according to a study conducted by the University of Cambridge and Fudan University involving 42,000 adults.

Drugs Health Research

Effects of loneliness, social isolation leave their mark on blood: Cambridge study

Loneliness may contribute to a higher risk of heart disease, stroke and susceptibility to infections, according to a study conducted by the University.